ClinicalTrials.gg
CompletedNCT07847268Updated Sep 29, 2026

A First-in-Human Study of ¹⁷⁷Lu-HX02 in Sarcoma Patients

An observational study in Sarcoma, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Observational

How we know

Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
9
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 133 studies in Sarcoma with a site in China — 68 open to participants now, 74 under way, 1 of them phase 3. Sarcoma · China.

Enrollment
10th of 11
9 · median 70
Started
2025
with 10 others
Observational
11 of 133
4 open now
Registered
128th of 133
by date

Among the 133 studies in Sarcoma with a site in China, this one is the 10th largest by enrollment of the 11 observational ones that give a count, is one of 11 that started in 2025, is one of 11 observational ones, and was the 128th registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

68 of the 133 studies in Sarcoma with a site in China are open now. Recruiting first, the newest first:

63 more — sign in →

All 68 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies in Sarcoma with a site in China, or all of them as a file.
02

Study summary

This is a single-center, open-label clinical study to evaluate the safety, biodistribution, and dosimetry of ¹⁷⁷Lu-HX02 injection in patients with sarcoma. Approximately 6 to 10 subjects with sarcoma (preferably soft tissue sarcoma and Ewing's sarcoma), confirmed by histopathology, cytology, or clinical diagnosis, and with measurable lesions according to RECIST 1.1, are planned to be enrolled. The enrollment requires that at least one measurable lesion has an SUVmax ≥ 3.5 on ⁶⁸Ga-HX01 injection imaging. Eligible subjects who meet the inclusion/exclusion criteria will receive a single intravenous administration of ¹⁷⁷Lu-HX02 injection, followed by SPECT/CT imaging to assess the safety, biodistribution, and dosimetry of the drug. The study consists of two phases: a screening phase with ⁶⁸Ga-HX01 and a treatment/evaluation phase with ¹⁷⁷Lu-HX02.

03

Conditions studied

  • Sarcoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The study population will consist of male and female patients aged between 18 and 70 years, with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1 and the ability to tolerate PET/MR and SPECT/CT examinations. Eligible patients must have a histopathologically, cytologically, or clinically confirmed diagnosis of sarcoma, with at least one measurable lesion according to RECIST 1.1 criteria. In addition, at least one measurable lesion must demonstrate an SUVmax ≥ 3.5 on [⁶⁸Ga]Ga-HX01 PET/MR imaging; final eligibility will be determined by the investigator and may be adjusted based on subsequent [¹⁷⁷Lu]Lu-HX02 SPECT/CT imaging findings.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must meet all of the following criteria:

    1. Voluntarily sign the written form prior to the initiation of any study-specific procedures;
    2. Age between 18 and 70 years, male or female;
    3. (ECOG) performance status score of 0-1, and able to tolerate PET/MR and SPECT/CT examinations;
    4. Histopathologically, cytologically, or clinically confirmed diagnosis of sarcoma, with at least one according to 1.1 criteria;
    5. At least one measurable lesion with SUVmax ≥ 3.5 on [68Ga]Ga-HX01 PET/MR imaging (eligibility to be determined by the investigator, and may be adjusted based on subsequent [177Lu]Lu-HX02 SPECT/CT imaging findings);
    6. ≥ 6 months;
    7. Female participants of must have a negative pregnancy test, and all participants (both male and female) must agree to use effective during the study and for at least 3 months after administration.

Exclusion criteria

Exclusion Criteria:

  • Participants who meet any of the following criteria will be excluded from the study:

    1. Women who are pregnant or breastfeeding, or who plan to become pregnant during the study or within 3 months after administration [excluding those who have been for at least 1 year, or who have undergone surgical sterilization (e.g., bilateral tubal ligation without reversal, bilateral oophorectomy, or hysterectomy)]; or participants (both male and female) who plan to donate sperm or ova during the study or within 3 months after administration;
    2. Known or suspected allergy to the product or any of its components, or severe allergic constitution;
    3. Have received any treatment within 6 months prior to screening that, in the investigator's judgment, may affect drug absorption, distribution, metabolism, or excretion;
    4. Positive syphilis or test at screening;
    5. Significant hepatic or renal dysfunction, defined as: serum total (TBIL) > 31.5 μmol/L; (AST) or alanine aminotransferase (ALT) > 120 U/L, or > 200 U/L if the elevation is considered to be related to hepatic from solid tumors; serum creatinine (Scr) > 150 μmol/L, or \< 60 mL/min (calculated by the Cockcroft-Gault formula);
    6. Abnormal bone marrow function, defined as: (ANC) \< 1.5 × 109/L; \< 10 g/dL; serum albumin \< 2.8 g/dL (normal range: 3.5-5.5 g/dL); count \< 100 × 10⁹/L (normal range: 100-300 × 109/L); (INR) > 1.5 (normal range: 0.8-1.3) in patients not receiving warfarin; prothrombin time (PT) > 2 × (normal range: 11-15 seconds);
    7. Presence of active infection (e.g., acute bacterial infection, tuberculosis, active /C, active syphilis, etc.). Active hepatitis B is defined as: positive HBsAg or HBcAb test with HBV DNA titer > 2500 copies/mL or 500 IU/mL. Active is defined as: positive hepatitis C antibody with detectable HCV-RNA;
    8. Difficulty in urination or urinary incontinence due to any cause;
    9. Claustrophobia or any other condition that prevents the subject from undergoing PET/MR and SPECT/CT examinations;
    10. Psychiatric disorders, such as depressive symptoms, schizophrenia, delusions, hallucinations, or suicidal ideation;
    11. Severe cardiovascular disease, including but not limited to (NYHA) class II-IV congestive heart failure or (LVEF) \< 50% or below the lower limit of normal;
    12. Any other condition that, in the investigator's opinion, makes the participant unsuitable for participation in this study.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
9 participants (actual)
Patient registry
No

Interventions

  • Diagnostic testSafety, Biodistribution, and Dosimetry of ¹⁷⁷Lu-HX02 in Patients with Sarcoma

    Subjects who meet the inclusion/exclusion criteria will receive an intravenous administration of ¹⁷⁷Lu-HX02 injection, followed by SPECT/CT imaging to evaluate the safety, biodistribution, and dosimetry of the drug.

06

What researchers measure

Primary outcomes

  1. Imaging Quantitative Assessment

    After a single intravenous injection of ¹⁷⁷Lu-HX02, descriptive SUV statistics (mean, max, SD, min, max) will be obtained from ROIs in the liver, kidneys, and tumor lesions, and the target-to-background ratio (TBR, tumor/normal tissue) will be calculated.

    Time frame: 1, 3, 6, 24, and 72 hour post-injection

  2. Safety Evaluation

    All adverse events (AEs) will be monitored post-injection and graded per CTCAE v5.0 (grades 1-5). The primary measure is the number and incidence (%) of treatment-related adverse events (TRAEs).

    Time frame: From baseline through 6 months post-injection

07

Study locations

1 site
  • Wuhan Union Hospital
    Wuhan, Hubei 430030, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Dec 2025, 9 months.

Of 88 non-industry observational studies under Sarcoma, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 47 and three quarters within 294. This study's 9 months is below that.

Counting every sponsor, half of 97 studies reached it within 66 months; a quarter within 42 and three quarters within 294.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2026
First posted
Sep 29, 2026
StartActual
Mar 1, 2025
Primary completionActual
Dec 31, 2025
CompletionActual
Dec 31, 2025
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07847268
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Mar 1, 2025
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025
Last update
Sep 29, 2026

Study contacts

Xiaoli Lan, PhD
study director · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion